<DOC>
	<DOC>NCT01603602</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.</brief_summary>
	<brief_title>BOTOX® Treatment in Pediatric Upper Limb Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Minimum weight of 10 kg/22 lb Upper limb spasticity due to cerebral palsy or stroke Muscular dystrophy, myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease Uncontrolled epilepsy Botulinum Toxin therapy of any serotype for any condition within the last 6 months Previous surgical treatment of the study limb (except tendon lengthening), or planned surgery of the study limb during the study Previous casting of the study limb for spasticity within 6 months or with a dynamic splint within 3 months, or planned casting or dynamic splinting for spasticity of the study limb or affected lower limb during the study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>